16

October 16, 2018

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 16/October/2018, 1.38 pm

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different […]
October 16, 2018

Mechanistic insights into how anesthetic agent Sevoflurane may deteriorate memory, learning, and cognition: Sevoflurane (trade name: Sojourn, Ultane, Sevorane), a local anesthetic agent, decreases Tissue inhibitor of metalloproteinases 2 (TIMP2) and BDNF levels, attenuates cognition, and aggravates age-associated decline in memory and learning, via up-regulation of its target genes, 16/October/2018, 1.18 pm

Introduction: What they say A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
October 16, 2018

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Niclosamide, Curcumin, Chlorpromazine, Procainamide, IP-504, and Salinomycin inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/October/2018, 12.42 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]
October 16, 2018

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 16/October/2018,12.17 pm

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows […]